Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, Gynecologic
Status:
Open
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
NCT#03660826
GY012 is reopened to accrual, effective May 23, 2022.
